Effect of Smoking on Blood Parameters and Thyroid Hormones in Men with Polycythemia

Marwah A. Majeed
Zainab A. Ridha Al-Ali

Department of Biology/ College of Science/ University of Misan/ Maysan/ Iraq

p-ISSN: 1608-9391
e-ISSN: 2664-2786

ABSTRACT

Smoking is the primary cause of fatalities, disabling conditions, and avoidable diseases worldwide. Smokers are subject exposed to a variety of dangerous compounds, which stimulate the bone marrow to produce more RBCs. So that, this study aims to know the effects of smoking on men with polycythemia by studying the blood parameters and thyroid hormones. The study is conducted on 100 men (75 with polycythemia and 25 men control), ages (20-59) years, with samples collected from the blood bank at Maysan governorate, from the period November 2022 to March 2023. The results showed an increase significant (P≤0.05) in the values of red blood cells, hemoglobin and hematocrit, while, the white blood cells count showed no significant (P≤0.05) differences for both groups of polycythemias (smokers and non-smokers) as compared to the control group. Also, mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration showed an increase significant (P≤0.05) in the smokers group. No significant (P≤0.05) variation was recorded in the values of thyroid stimulating hormone and thyroxine among groups, and triiodothyronine values in polycythemia (smoker and non-smoker) increased significantly (P≤0.05) in comparison with the control group. According to the above results we conclude the smoking effect in blood parameters and T3 hormones in smoker polycythemia men.

Keywords: smoking, hemoglobin, polycythemia, thyroid, hormone.

This is an open access article under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
INTRODUCTION

Smoking is the primary cause of fatalities, disabling conditions, and avoidable diseases worldwide. In the United States, it causes more than 480,000 fatalities annually, or about one in every five deaths (Jamal et al., 2018).

Smoking cigarettes increases the chance of developing cardiovascular disorders such as peripheral vascular disease, atherosclerosis, myocardial infarction, stroke, and coronary artery disease (Malenica et al., 2017). The exact process by which smoking causes these disorders in smokers is unknown, but it is believed that abnormalities in blood rheology, infections, inflammation, oxidative stress, changes in the fibrinolytic system, and antithrombotic systems are to blame (Malenica et al., 2017). According to the (Ahmad and Al-Helaly, 2009), the smoking causes oxidative stress in smoker persons when study was conducted at suburbs Mosul City.

Smokers are exposed to a variety of dangerous compounds, such as nicotine, free radicals, carbon monoxide (CO), and other gaseous pollutants (Gitte, 2011).

Hemoglobin (Hb) and Hematocrit (Hct) levels rise as a result of the effects of tobacco and CO on tissue oxygen supply as well as, stimulate bone marrow to produce more RBCs (Roethig et al., 2010), increased production of RBCs, and a very high RBC mass decreases blood flow, and increases the risk of intravascular coagulation, coronary vascular resistance, decreased coronary blood flow, and a propensity to thrombosis (Raval and Paul, 2010).

The thyroid gland is classical endocrine gland located in the anterior neck in front of the trachea. It is essential for the body's healthy development, differentiation, metabolism, and physiological performance. In clinical practice, thyroid dysfunction is one of the most frequent disorders, and it has become more widespread globally in recent years, thus its risk factors have drawn a lot of attention (Garmendia et al., 2014; Taylor et al., 2018).

Thyroid disorders can result in a variety of symptoms, such as the hypoplasia of erythroid cells in the bone marrow, the proliferation of immature erythroid progenitor cells (due to hypothyroidism), or the hyperplasia (related to hyperthyroidism) (Kawa et al., 2010).

Previous research showed that thyroid malfunction can cause anemia, erythrocytosis, leukopenia, thrombocytopenia, and, in rare cases, pancytopenia in blood cells (Davis et al., 1983).

Thyroid hormones stimulate the growth of erythroid colonies (BFU-E, CFU-E), increase erythrocyte 2, 3 Diphosphoglycerate (DPG) compactness, enhance erythropoiesis through a hyper proliferation of immature erythroid progenitors, increase erythropoietin (EPO) secretion by inducing EPO gene expression, and contribute to hemoglobin production, effect on megakaryocytes through modulation of bone marrow matrix proteins, such as fibronectin, increase the expression of fibronectin gene, alter platelet function and affects hematopoiesis in many ways (Dorgalaleh et al., 2013; Jp and Srikrishna, 2012).

MATERIALS AND METHODS

Subject

The present study was carried out in the blood bank at Maysan governorate. The study population comprised 100 men aged between 20-59 year, (75) men with polycythemia and (25) men who was normally healthy a control from November 2022 to March 2023.

Blood Sample

Blood vein (5 - 6 ml) were taken from all subjects then divided into two and transferred into EDTA tube for complete blood count (CBC) determination and other part was transferred into gel tube for hormonal study. The red blood cells (RBCs) count, hematocrit (Hct), hemoglobin concentration (Hb), white blood cells (WBCs) count, and estimation of red blood indices mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) were obtained directly from automatic hematological analyzer (Spin cell 3) apparatus.
The CL-series Thyroid Stimulating Hormone (TSH), Thyroxine Hormone (T\textsubscript{4}) and Triiodothyronine Hormone (T\textsubscript{3}) assay are a Chemiluminescent Immunoassay Analyzer (CLIA) for the quantitative determination of hormones in serum (Bermudez et al., 1975; Fisher, 1996; Keffer, 1996).

**Statistical Analysis**

The data was analyzed statistically to known the significance of the different parameters by one way ANOVA, the difference was considered to be significant at $P\leq 0.05$ the values present as means ± SE (Bryman and Cramer, 2012).

**RESULTS**

**Hematological Parameters**

The results of present study showed increase significant ($P \leq 0.05$) in the values of RBC, Hb and Hct (5.08 ± 0.05 $10^6$/mm$^3$, 5.03 ± 0.05 $10^6$/mm$^3$, 17.21± 0.10 g/dL, 16.74± 0.10 g/dL and 55.07± 0.28%, 53.6 ± 0.25% respectively). While, the values of WBCs (7.63 ± 0.27 $10^3$/ mm$^3$, 7.5 ± 0.40 $10^3$/ mm$^3$, respectively) showed no significant ($P\leq 0.05$) differences for both groups of polycythemias (smokers and non-smokers) as compared to the control group (4.71± 0.08 $10^6$/mm$^3$, 14.34 ± 0.06 g/dL, 46.50 ± 0.33% and 6.86 ± 0.31 $10^6$/mm$^3$, respectively) (Table 1).

MCV, MCH and MCHC (107.90 ± 0.75 fl, 33.83 ± 0.29 pg and 31.36± 0.01 g/dL respectively) showed increase significant ($P\leq 0.05$) in smokers’ group as compared to the control group (103.76 ± 2.27 fl, 32.05 ± 0.82 pg and 30.83 ± 0.19 g/dL respectively). But, MCV and MCH in non-smokers (105.74 ± 0.96 fl and 33.26 ± 0.37 pg) showed no significant ($P\leq 0.05$) between non-smokers and control group (Table 2).

**Table 1: The values of blood parameters in male with polycythemia and control groups**

<table>
<thead>
<tr>
<th>Parameters Groups</th>
<th>RBC\textsubscript{S} ($10^6$/mm$^3$)</th>
<th>Hb (g/dL)</th>
<th>HCT (%)</th>
<th>WBC\textsubscript{S} ($10^3$/mm$^3$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>4.71± 0.08 b</td>
<td>14.34 ± 0.06 c</td>
<td>46.50 ± 0.33 c</td>
<td>6.86 ± 0.31 a</td>
</tr>
<tr>
<td>Smokers Polycythemia</td>
<td>5.08 ± 0.05 a</td>
<td>* 17.21± 0.10 a</td>
<td>55.07± 0.28 a</td>
<td>7.63 ± 0.27 a</td>
</tr>
<tr>
<td>Non smokers Polycythemia</td>
<td>5.03 ± 0.05 a</td>
<td>* 16.74± 0.10 b</td>
<td>53.6 ± 0.25 b</td>
<td>7.5 ± 0.40 a</td>
</tr>
</tbody>
</table>

Means ±SE

*The different letters refer to the significant differences among group at level of ($p < 0.05$)
The similar letters refer to non-significant among group difference at level of ($p < 0.05$).
Table 2: The values of Red Blood Cells (RBCs) indices in men with polycythemia and control group

<table>
<thead>
<tr>
<th>Parameters</th>
<th>MCV (fL)</th>
<th>MCH (pg)</th>
<th>MCHC (g/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>103.76 ± 2.27 b</td>
<td>32.05 ± 0.82 b</td>
<td>30.83 ± 0.19 b</td>
</tr>
<tr>
<td>Smokers Polycythemia</td>
<td>107.90 ± 0.75 a</td>
<td>33.83 ± 0.29 a</td>
<td>31.36 ± 0.01 a</td>
</tr>
<tr>
<td>Non smokers Polycythemia</td>
<td>105.74 ± 0.96 ab</td>
<td>33.26 ± 0.37 ab</td>
<td>31.48 ± 0.21 a</td>
</tr>
</tbody>
</table>

Means ±SE
*The different letters refer to significant difference among group at level of (p ≤ 0.05)
The similar letters refer to non-significant difference among group at level of (p ≤ 0.05).

Hormonal Parameters
Non-significant (p≤0.05) variation was recorded in the levels of TSH in the smoker and non-smoker groups (2.75 ± 0.23, 2.54 ± 0.21 µlU/ml, respectively) in comparison with the control group (2.95 ± 0.22 µlU/ml) as shown in Fig. (1).

Non-significant (p≤0.05) variation was recorded in the levels of T4 in the smoker and non-smoker groups (8.05 ± 0.21, 7.74 ± 0.33 µg/dl, respectively) in comparison with the control group (8.36 ± 0.27 µg/dl) as shown in Fig. (2).

The T3 levels in smoker (0.86 ± 0.02 ng/dl) and non-smoker groups (0.88 ± 0.02 ng/dl) were increased significantly (P≤0.05) in comparison with control group (0.80 ± 0.02 ng/dl). While, did not differ significantly (p≤0.05) between smoker and non-smoker group as shown in Fig. (3).

Fig. 1: The levels of Thyroid Stimulating hormone (TSH) in men with polycythemia (smokers and non-smokers) and control
Fig. 2: The levels of Thyroxine (T4) in men with polycythemia (smokers and non-smokers) and control

Fig. 3: The levels of Triiodothyronine (T3) in men with polycythemia (smokers and non-smokers) and control

**DISCUSSION**

The results of the present study agree with a study done by (Raval and Paul, 2010), they showed very high RBC mass and a high quantity of RBCs in smokers polycythemia. Also, observed that smokers had significantly higher Hb the concentration. In fact, higher Hb concentrations are linked to higher RBCs counts or sizes. RBCs levels were noticeably higher in smokers compared to non-smokers (Tarazi *et al.*, 2008). According to another study, higher RBCs and Hct levels are associated with higher blood viscosity and coagulation in smokers (Ho, 2004).

In comparison to non-smokers, smokers' Hb values were noticeably higher (Kume *et al.*, 2009). Increased Hct levels have been linked to polycythemia and a higher risk of atherosclerosis progression and cardiovascular disease (Ferro *et al.*, 2004). The important experimental disparities revealed in the blood parameters (RBCs, Hb, and HCT) in subject’s smokers in comparison with non-smokers, according to the study by (Asif *et al.*, 2013). Other studies agree with the results of our study, they show that Hb and Hct were considerably greater in smokers than in non-smokers, and that polycythemia was observed in 7.02% of all individuals (8.42% of smokers versus 6.54% of non-smokers) (Kung *et al.*, 2008).

The effect of smoking on the blood parameter may be due to CO released from smoke binds with hemoglobin to form carboxyhemoglobin (COHb), which affects tissue hypoxia and increases erythropoietin production and erythropoiesis. Plasma volume decreases in response to CO elevation of capillary permeability, similar to relative polycythemia (Pankaj *et al.*, 2014).
Smokers have higher (COHb) concentrations, which cause progressive hypoxia and changes to the hematological parameters (Lakshmi et al., 2014). CO is produced by the inefficient use of carbon-containing materials, as in the state of cigarette smoking in comparison to oxygen, CO is thought to have an affinity for hemoglobin that is around 200 times higher (Carallo et al., 1998). As a result, COHb complex which inhibits the release of Oxygen from hemoglobin to tissue, forms when CO combines with hemoglobin rather than Oxygen in the erythrocyte (Cronenberger et al., 2008).

The number of cigarettes smoked per day increases, the mean Hb concentration and HbCO levels gradually rise. Additionally, the duration of chronic exposure to HbCO is linked to the development of polycythemia (Leifert, 2008).

Smoking has been observed to generate a unique state of linked polycythemia to chronic hypoxia, increasing the release of erythrocytes due to an increase in HbCO, and causing a decrease in plasma volume (Raval and Paul, 2010), this causes increase in Hct and Hb levels, which are thought to be a compensation strategy for CO exposure (Roethig et al., 2010). When exposed the animals to the passive smoking exposure for different periods, they found a significant decrease (p≤0.05) in the total number of white blood cells and a significant increase (p≤0.05) in each of packed cell volume and Hb concentration in groups exposed to cigarettes smoking as compared with control group (Al-Attar and Jihad, 2013).

On the contrary, they showed that the WBCs count in smokers with polycythemia increased significantly than non-smokers (Al Dayyeni et al., 2023).

Another study suggested that the elevated leukocyte count may be caused by nicotine's catabolic release of catecholamine, which raises blood lymphocyte numbers, the irritating effects of cigarette smoke on the respiratory system and the ensuing inflammation may also be contributing factors to a higher WBCs count, additionally, it has been proposed that inflammation-stimulating the bronchial tract causes blood circulation to produce more inflammatory markers (Calapai et al., 2009).

The MCV, MCH, and MCHC levels were increased significantly in men smokers compared to control, these results are in agreement with study of (Inal et al., 2014) about the effects of smoking on hematological parameters, smokers' MCV values were higher than MCV in nonsmokers. Also, they noted that smokers' MCV levels of RBCs macrocytosis were higher than those of non-smokers. Moreover, it is shown that smokers have higher levels of MCV, MCH, MCHC, and COHb, which can increase blood viscosity and vascular loading, resulting in RBC macrocytosis and hyperchromia (Kung et al., 2008).

While, observed no significant differences in MCV and MCH between smokers and non-smokers, but they found a significant decline in MCHC values among smokers (Pankaj et al., 2014).

In contrast, the study of (Salamzadeh, 2004) showed the amounts of MCH and MCHC values in the smoker group were markedly decreased in comparison to those of the non-smoker group.

Our study shown no significance for the levels of TSH and T4 and increase significance in men smokers and non-smokers compared to the control group, this result is consistent with the previous study, which indicates that smoking has an impact on the pituitary gland's operation and increases the levels of several of its hormones, such as growth hormone (GH) and adrenocorticotropic (ACTH), but has no impact on TSH levels (Kapoor and Jones, 2005). While, in another study the level of TSH in smokers' serum is lower than those of controls (Jorde and Sundsfjord, 2006).

These results agree with a study performed by Fisher and his group (1997) that they found no significant effect of smoking on T4 levels. Contrary to findings from another study, they noted that smokers' T4 levels were higher than those of non-smokers' (Kadkhodazadeh et al., 2020).

They found higher in serum level of T3 in smokers when compared to the control (Ahmadi et al., 2012 ). Another study investigating the influence of smoking on thyroid hormone
levels have observed an increase in T₃ levels in smokers compared with non-smokers (Gruppen et al., 2020). The results of previous studies are agreed with our study.

The people who smoke heavily, the serum level of T₃ compared to non-smoking, it has been significant decreased according to study by (Pradhan et al., 2020). As a thyroid stimulant, nicotine has been used. The hypothalamic-pituitary-thyroid axis is another highly active system that nicotine can stimulate. It imitates acetylcholine's effects at specific central nicotine acetylcholinergic receptors, activating the sympathetic nervous system, which then stimulates the thyroid gland and increases T₃ output. Smokers' lower serum levels of thyroid stimulating hormone are due to its suppression by the elevated levels of serum T₃ because of negative feedback regulation (Balhara and Deb, 2014).

The mechanism through which cigarette smoking affects TSH and thyroid hormone levels is still unclear. This is not surprising since there are more than 4000 components in tobacco. Several studies have suggested that smoking lessens thyroid autoimmune processes (Wiersinga, 2013), causing changes in TSH and T₃ levels. Also proposed is a relationship between rising T₃ levels and falling TSH levels (Cryer et al., 1976) a result of smokers’ elevated sympathetic nerve activity (Melander et al., 1977).

**CONCLUSION**

The current study concluded that smoking causes an increase in hematological parameters (red blood cells, hemoglobin and hematocrit) in men with polycythemia smoker and non-smoker due to an increase in the production of red blood cells from the bone marrow. In other hand the changes in the values of red blood cells indices in men with polycythemia smoker and non-smoker was higher specially in mean corpuscular hemoglobin concentration. Also, the results observed that the T₃ hormone increased in men with polycythemia smoker and non-smoker, while the T₄ and TSH hormones were not affected in smoker Polycythemia men, this maybe explain the role of smoking on hypothalamus pituitary thyroid axis.

**REFERENCES**


Calapai, G.; Caputi, A.P.; Mannucci, C.; Russo, G.A.; Gregg, E.; Puntoni, R.; Nunziata, A. (2009). Cardiovascular biomarkers in groups of established smokers after a decade of


تأثير التدخين على معايير الدم وهرمونات الغدة الدرقية عند الرجال المصابين بكثرة كريات الدم الحمراء

زيوب عبد الجبار رضا العلي
قسم علوم الحياة/ كلية العلوم/ جامعة ميسان/ ميسان/ العراق

المملوء

بعد التدخين السبب الرئيسي للوفيات، حالات الإعاقة والأمراض التي يمكن الوقاية منها في جميع أنحاء العالم، يتعرض المدخنون لمجموعة متنوعة من المركبات الخطرة والتي تحفز نخاع العظام لإنتاج المزيد من كرات الدم الحمر، لذا هدفت هذه الدراسة إلى معرفة تأثير التدخين على الرجال المصابين بكثرة الحمر من خلال دراسة ماستر الدم وهورمونات الغدة الدرقية. أجريت الدراسة على 101 رجل (75 مصابين بكثرة الحمر و 25 رجلاً سليمين) تتراوح أعمارهم بين (20-59) سنة، تم جمع العينات من بنك الدم في محافظة ميسان، للفترة من تشرين الثاني 2022 إلى آذار 2023.

أظهرت النتائج زيادة معنوية في قيم كريات الدم الحمر وخضاب الدم وحجم خلايا الدم المرصودة لكل مجموعتي كثرة الحمر (المدخنين وغير المدخنين) مقارنة بمجموعة السيطرة، لم تظهر كريات الدم البيض فروقات معنوية مقارنة بمجموعة السيطرة. كما أظهرت دائرة الكريزة زيادة معنوية مقارنة مع مجموعة السيطرة. لم تتسجيل اختلافات معنوية في قيم الهرمون المحفز للدرقية وهرمون الثيروكسين بين مجموعتي الرجال المصابين بكثرة الحمر (مدخنين وغير مدخنين)، أما بالنسبة إلى هرمون ثلاثي يود الثيرونين، ازداد معنويًا لكلا مجموعتي كثرة الحمر (المدخنين وغير المدخنين) مقارنة بمجموعة السيطرة. من النتائج أعلاه يمكن الاستنتاج بأن التدخين له تأثير على معايير الدم وهورمونات الدرقية عند الرجال الذين يعانون من كثرة كريات الدم الحمر.

الكلمات الدالة: التدخين، الهيموجلوبين، كثرة الحمراء، الدرقية، هورمونات.